BURU vs LYRA vs IPGP vs XNCR

For growth investors, Xencor, Inc.

(XNCR) is the stronger pick with 13. 7% revenue growth year-over-year, versus -92. 7% for Nuburu, Inc. (BURU). IPG Photonics Corporation (IPGP) offers the better valuation at 139. 2x trailing P/E (62. 6x forward), making it the more compelling value choice. Analysts rate IPG Photonics Corporation (IPGP) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, IPG Photonics Corporation (IPGP) delivered a total return of -48.

5%, compared to -99. 9% for Nuburu, Inc. (BURU). Over 10 years, the gap is even starker: IPGP returned +20. 2% versus LYRA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lyra Therapeutics, Inc.

(LYRA) is the lower-risk stock at 0. 65β versus Xencor, Inc. 's 1. 99β — meaning XNCR is approximately 209% more volatile than LYRA relative to the S&P 500. On balance sheet safety, Xencor, Inc. (XNCR) carries a lower debt/equity ratio of 30% versus 3% for Lyra Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xencor, Inc.

(XNCR) is pulling ahead at 13. 7% versus -92. 7% for Nuburu, Inc. (BURU). On earnings-per-share growth, the picture is similar: IPG Photonics Corporation grew EPS 117. 8% year-over-year, compared to -13. 5% for Lyra Therapeutics, Inc.. Over a 3-year CAGR, LYRA leads at 75. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IPG Photonics Corporation (IPGP) is the more profitable company, earning 3.

1% net margin versus -226. 9% for Nuburu, Inc. — meaning it keeps 3. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IPGP leads at 1. 3% versus -86. 4% for BURU. At the gross margin level — before operating expenses — LYRA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for XNCR: 162.

6% to $32. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lyra Therapeutics, Inc.

(LYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65)). Xencor, Inc. (XNCR) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LYRA: -100. 0%, XNCR: +4. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BURU (Industrials) and LYRA (Healthcare) and IPGP (Technology) and XNCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.